Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: Yahoo Finance
- New Scientific Advisor: Harbour BioMed has appointed Dr. Luisa Salter-Cid as Scientific Advisor, bringing over 20 years of leadership experience in biotech and pharmaceuticals, which is expected to enrich the company's expertise and strategic direction.
- Clinical Development Achievements: During her tenure at Bristol Myers Squibb, Salter-Cid successfully advanced over 20 compounds into clinical development, showcasing her exceptional ability to translate discoveries into clinical applications, which will help accelerate Harbour BioMed's antibody therapeutic pipeline.
- Technological Platform Advantage: Harbour BioMed's Harbour Mice® technology platform generates fully human monoclonal antibodies, and combined with HCAb technology, it offers tumor-killing effects that traditional combination therapies cannot achieve, with Salter-Cid's expertise likely enhancing its application potential.
- Global Medical Needs: Salter-Cid's strategic insights will assist Harbour BioMed in addressing unmet medical needs globally, driving the company's efforts in innovative drug development, thereby enhancing its market competitiveness and industry standing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 56.480
Low
37.00
Averages
55.86
High
68.00
Current: 56.480
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
- New Scientific Advisor: Harbour BioMed has appointed Dr. Luisa Salter-Cid as Scientific Advisor, bringing over 20 years of leadership experience in biotech and pharmaceuticals, which is expected to enrich the company's expertise and strategic direction.
- Clinical Development Achievements: During her tenure at Bristol Myers Squibb, Salter-Cid successfully advanced over 20 compounds into clinical development, showcasing her exceptional ability to translate discoveries into clinical applications, which will help accelerate Harbour BioMed's antibody therapeutic pipeline.
- Technological Platform Advantage: Harbour BioMed's Harbour Mice® technology platform generates fully human monoclonal antibodies, and combined with HCAb technology, it offers tumor-killing effects that traditional combination therapies cannot achieve, with Salter-Cid's expertise likely enhancing its application potential.
- Global Medical Needs: Salter-Cid's strategic insights will assist Harbour BioMed in addressing unmet medical needs globally, driving the company's efforts in innovative drug development, thereby enhancing its market competitiveness and industry standing.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
Commercialization Prospects of Space Pharmaceuticals
- Space Drug Development: SpaceMD CEO John Vellinger stated that utilizing the space environment can resolve hundreds of drug compounds sidelined annually due to crystallization errors, which is expected to have an immediate impact on the pharmaceutical industry.
- Technological Innovation: SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, demonstrating that crystals grown in zero gravity are more uniform and stable, thereby enhancing drug usability and absorption rates.
- Market Potential: Morgan Stanley predicts that the space economy will exceed $1 trillion by 2040, with the pharmaceutical sector being one of the first beneficiaries, as commercial opportunities continue to expand with the establishment of necessary infrastructure.
- International Collaboration: The UK Space Agency is investing in projects exploring the feasibility of manufacturing drugs in space, with BioOrbit developing scalable systems for crystallizing and manufacturing complex biologics, driving innovation in the drug market.
See More
AbbVie: A Steady Dividend Growth Stock
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Dividend Yield: Currently, AbbVie offers a forward dividend yield of around 3%, providing a relatively high yield given its share price, while trading at approximately 16 times forward earnings, which remains attractive compared to peers.
- Earnings Expectations: AbbVie is projected to report adjusted earnings of $10 per share in 2025, increasing to $16.23 per share by 2027, indicating strong earnings growth potential, especially as competitors like Pfizer face expected declines.
- Sustainable Dividend Policy: With a payout ratio of 42%, AbbVie operates within sustainable levels, and its recent dividend growth averaging 5% to 6% suggests the likelihood of continued increases, appealing to long-term investors.
See More
AbbVie: A Steady Dividend Growth Star
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Current Dividend Yield: AbbVie currently offers a forward dividend yield of approximately 3%, providing a relatively high return at its share price level, which appeals to income-seeking investors.
- Strong Earnings Outlook: AbbVie is expected to report adjusted earnings of around $10 per share in 2025, increasing to $16.23 per share by 2027, indicating the company's ability to achieve earnings growth despite facing a patent cliff, which boosts investor confidence.
- Sustainable Payout Ratio: With a payout ratio of 42%, AbbVie remains within sustainable levels, and combined with recent dividend growth averaging 5% to 6%, it suggests the company can continue to increase dividends, attracting long-term investors.
See More
Millennium Management Boosts Stake in Bristol Myers Squibb
- Increased Holdings: Millennium Management raised its stake in Bristol Myers Squibb by over 5.8 million shares last quarter, indicating a bullish outlook for the pharmaceutical giant's future, even though this position represents less than 0.2% of its total assets.
- Stock Recovery: Bristol Myers Squibb's stock surged approximately 25% from late 2025 to early 2026, primarily driven by better-than-expected quarterly earnings and guidance, although it has recently pulled back due to uncertainties surrounding patent expirations.
- Financial Outlook: The company reiterated its full-year revenue guidance of $46 billion to $47.5 billion and adjusted earnings per share of $6.05 to $6.35 for 2026, demonstrating resilience and strategic planning in the face of a patent cliff.
- Innovation and AI Utilization: Bristol Myers Squibb is leveraging artificial intelligence to reduce costs and expedite clinical development, and while facing patent expiration challenges, its strategic measures may effectively mitigate impacts and bolster market confidence.
See More
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
- New Scientific Advisor: Harbour BioMed has appointed Dr. Luisa Salter-Cid as Scientific Advisor, bringing over 20 years of leadership experience in biotech and pharmaceuticals, which is expected to enrich the company's expertise and strategic direction.
- Clinical Development Achievements: During her tenure at Bristol Myers Squibb, Salter-Cid successfully advanced over 20 compounds into clinical development, showcasing her exceptional ability to translate discoveries into clinical applications, which will help accelerate Harbour BioMed's antibody therapeutic pipeline.
- Technological Platform Advantage: Harbour BioMed's Harbour Mice® technology platform generates fully human monoclonal antibodies, and combined with HCAb technology, it offers tumor-killing effects that traditional combination therapies cannot achieve, with Salter-Cid's expertise likely enhancing its application potential.
- Global Medical Needs: Salter-Cid's strategic insights will assist Harbour BioMed in addressing unmet medical needs globally, driving the company's efforts in innovative drug development, thereby enhancing its market competitiveness and industry standing.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
Commercialization Prospects of Space Pharmaceuticals
- Space Drug Development: SpaceMD CEO John Vellinger stated that utilizing the space environment can resolve hundreds of drug compounds sidelined annually due to crystallization errors, which is expected to have an immediate impact on the pharmaceutical industry.
- Technological Innovation: SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, demonstrating that crystals grown in zero gravity are more uniform and stable, thereby enhancing drug usability and absorption rates.
- Market Potential: Morgan Stanley predicts that the space economy will exceed $1 trillion by 2040, with the pharmaceutical sector being one of the first beneficiaries, as commercial opportunities continue to expand with the establishment of necessary infrastructure.
- International Collaboration: The UK Space Agency is investing in projects exploring the feasibility of manufacturing drugs in space, with BioOrbit developing scalable systems for crystallizing and manufacturing complex biologics, driving innovation in the drug market.
See More
AbbVie: A Steady Dividend Growth Stock
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Dividend Yield: Currently, AbbVie offers a forward dividend yield of around 3%, providing a relatively high yield given its share price, while trading at approximately 16 times forward earnings, which remains attractive compared to peers.
- Earnings Expectations: AbbVie is projected to report adjusted earnings of $10 per share in 2025, increasing to $16.23 per share by 2027, indicating strong earnings growth potential, especially as competitors like Pfizer face expected declines.
- Sustainable Dividend Policy: With a payout ratio of 42%, AbbVie operates within sustainable levels, and its recent dividend growth averaging 5% to 6% suggests the likelihood of continued increases, appealing to long-term investors.
See More
AbbVie: A Steady Dividend Growth Star
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Current Dividend Yield: AbbVie currently offers a forward dividend yield of approximately 3%, providing a relatively high return at its share price level, which appeals to income-seeking investors.
- Strong Earnings Outlook: AbbVie is expected to report adjusted earnings of around $10 per share in 2025, increasing to $16.23 per share by 2027, indicating the company's ability to achieve earnings growth despite facing a patent cliff, which boosts investor confidence.
- Sustainable Payout Ratio: With a payout ratio of 42%, AbbVie remains within sustainable levels, and combined with recent dividend growth averaging 5% to 6%, it suggests the company can continue to increase dividends, attracting long-term investors.
See More
Millennium Management Boosts Stake in Bristol Myers Squibb
- Increased Holdings: Millennium Management raised its stake in Bristol Myers Squibb by over 5.8 million shares last quarter, indicating a bullish outlook for the pharmaceutical giant's future, even though this position represents less than 0.2% of its total assets.
- Stock Recovery: Bristol Myers Squibb's stock surged approximately 25% from late 2025 to early 2026, primarily driven by better-than-expected quarterly earnings and guidance, although it has recently pulled back due to uncertainties surrounding patent expirations.
- Financial Outlook: The company reiterated its full-year revenue guidance of $46 billion to $47.5 billion and adjusted earnings per share of $6.05 to $6.35 for 2026, demonstrating resilience and strategic planning in the face of a patent cliff.
- Innovation and AI Utilization: Bristol Myers Squibb is leveraging artificial intelligence to reduce costs and expedite clinical development, and while facing patent expiration challenges, its strategic measures may effectively mitigate impacts and bolster market confidence.
See More
